Jazz Pharmaceuticals shared a post on LinkedIn:
“The FDA’s accelerated approval of a treatment for recurrent H3 K27M-mutant diffuse midline glioma is a powerful step forward for the rare cancer community. This milestone shows that innovation is possible, even in the toughest cases like these.
Learn more about what this milestone means for this rare brain cancer.”
More posts featuring Jazz Pharmaceuticals on OncoDaily.